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Abstract
Background: Adipose tissue inflammation fuels the metabolic syndrome. We recently reported that CD40L – an established
marker and mediator of cardiovascular disease – induces inflammatory cytokine production in adipose cells in vitro. Here,
we tested the hypothesis that CD40L deficiency modulates adipose tissue inflammation in vivo.
Methodology/Principal Findings: WT or CD40L
2/2 mice consumed a high fat diet (HFD) for 20 weeks. Inflammatory cell
recruitment was impaired in mice lacking CD40L as shown by a decrease of adipose tissue macrophages, B-cells, and an
increase in protective T-regulatory cells. Mechanistically, CD40L-deficient mice expressed significantly lower levels of the
pro-inflammatory chemokine MCP-1 both, locally in adipose tissue and systemically in plasma. Moreover, levels of pro-
inflammatory IgG-antibodies against oxidized lipids were reduced in CD40L
2/2 mice. Also, circulating low-density
lipoproteins and insulin levels were lower in CD40L
2/2 mice. However, CD40L
2/2 mice consuming HFD were not protected
from the onset of diet-induced obesity (DIO), insulin resistance, and hepatic steatosis, suggesting that CD40L selectively
limits the inflammatory features of diet-induced obesity rather than its metabolic phenotype. Interestingly, CD40L
2/2 mice
consuming a low fat diet (LFD) showed both, a favorable inflammatory and metabolic phenotype characterized by
diminished weight gain, improved insulin tolerance, and attenuated plasma adipokine levels.
Conclusion: We present the novel finding that CD40L deficiency limits adipose tissue inflammation in vivo. These findings
identify CD40L as a potential mediator at the interface of cardiovascular and metabolic disease.
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Introduction
The incidence of the metabolic syndrome (MS) and its
subsequent cardiovascular complications are on the rise worldwide
[1]. The MS comprises a cluster of risk factors including visceral
obesity, insulin resistance, dyslipidemia, hyperglycemia, hyperten-
sion, and hepatic steatosis [2,3]. Recent evidence demonstrates
that visceral obesity associates with chronic low-grade inflamma-
tion and up-regulation of inflammatory signaling pathways in
adipose tissue [4]. In line with this, adipose tissue has been
reported to act as an active endocrine and immune organ
efficiently secreting various adipokines including the pro-inflam-
matory cytokines TNFa and IL-6, the chemokine monocyte
chemoattractant protein (MCP)-1, and the procoagulant plasmin-
ogen activator inhibitor (PAI)-1 [5,6,7,8]. Several reports indicate
that inflammatory and immune cells such as T-cells and their
subsets, B-cells, macrophages, and mast cells accumulate in
adipose tissue during diet-induced obesity (DIO) and orchestrate
adipose tissue inflammation [9,10,11,12,13,14,15]. Impaired lipid
metabolism and triglyceride storage by adipocytes is a result of
adipose tissue inflammation and excess of free fatty acids
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inflamed adipose tissue propagates a systemic inflammation
predisposing for insulin resistance and cardiovascular pathologies
such as atherosclerosis [17,18]. Although strong evidence
identified inflammation as the key modulator of the metabolic
syndrome, exact immunological pathways mediating inflammato-
ry cascades in adipose tissue remain poorly understood [19].
CD40L, a member of the Tumor Necrosis Factor (TNF)
superfamily, acts as powerful mediator of adaptive and innate
immunity [20]. Beyond its function in immunity and co-
stimulatory pathways, CD40L plays a crucial role in a variety of
chronic inflammatory pathologies including inflammatory bowel
disease, multiple sclerosis, and rheumatoid arthritis [21]. Further-
more, CD40L and its downstream signaling adaptors, such as
TNF receptor-associated factors (TRAFs), are potent regulators of
atherosclerosis and cardiovascular disease [22,23,24,25,26]. We
and others recently demonstrated that plasma levels of sCD40L
associate with visceral obesity and adipokines. Moreover, CD40L
correlates with traditional cardiovascular risk factors, such as
insulin resistance and hypercholesterolemia [27,28,29,30]. On a
mechanistic level, our group and others previously demonstrated
that CD40L induces inflammatory cytokine expression in
adipocytes, adipogenesis, and the expression of the adipose
transcription factors C/EBPa, PPARc, and Sox-9 in Murine
3T3L1-cells and primary human adipocytes in vitro [27,31].
Notably, CD40 receptor was found to be expressed on human
pre-adipocytes and adipocytes and gene expression of CD40 in
visceral adipose tissue correlated with body mass index. In the light
of these data, we hypothesized that CD40L deficiency modulates
adipose tissue inflammation in vivo.
Results
CD40L deficiency reduces weight gain on low fat diet,
but does not prevent the onset of obesity on high fat
diet
To determine the role of CD40L in diet-induced obesity (DIO)
wild type (WT) and CD40L
2/2 mice consumed either low fat
(LFD) or high fat diet (HFD) for 20 weeks. CD40L
2/2 mice
consuming LFD for 20 weeks gained significantly less weight than
respective wild type controls throughout the study, resulting in a
reduction of body weight gain by 2368% (p=0.006, n$15 per
group, Figure S1 A). Accordingly, after 20 weeks on LFD relative
body fat of CD40L
2/2 mice was decreased by 2967% as assessed
by MRI-based body composition analysis (p=0.0004, n$15 per
group, Figure S1 B). On HFD, absence of CD40L did not affect
body weight gain during the first 12 weeks of the study, but
significantly increased weight gain at the late stages of DIO by up
to 1266% (p=0.04, n=35 per group, Figure 1A). Relative body
fat content was slightly reduced during early stages but did not
differ at the end of the study (Figure 1 B).
In line with these data, CD40L
2/2 mice consuming LFD for 20
weeks contained significantly less peri-renal fat than respective
wild-type controls (Figure S1 C), while CD40L
2/2 mice
consuming HFD for 20 weeks contained similar or modestly
increased epididymidal fat (Fig. 1 C). Accordingly, plasma leptin
levels decreased in the HFD group at week 8 of DIO, but did not
significantly differ at the end of the study (Figure 2 A), while
adiponectin increased in CD40L-deficient mice after HFD
(Figure 2 B). On LFD, plasma leptin was reduced at both time
points (Figure S1 D). These effects on DIO could not be attributed
to changes in energy metabolism since plasma food intake and
heat production assessed by metabolic caging did not differ
between both genotypes under both dietary regimens (Figure 2 C–
D, Figure S1 E–G). Interestingly, ambulatory movement was even
slightly increased in CD40L
2/2 mice consuming HFD (by up to
39613%, p=0.01, n$20 per group, Figure 2E). Respiratory
exchange ratio (RER) was not significantly altered in both groups
independently of the diet consumed (Figure 2 F, Figure 1 H). As
expected, RER was overall lower in HFD-groups with no
detectable difference between WT and CD40L
2/2 mice. Growth
hormone secretion is blunted in obesity [32] and might account for
differences in growth and weight. Levels of somatostatin
decreased, while levels of growth hormone releasing hormone
(GnRH) and Insulin-like growth factor (IGF-1) increased in
CD40L-deficient mice consuming LFD (Figure S1 I–K), suggest-
ing a role for CD40L in growth hormone regulation. However,
differences in growth hormone levels were not observed in
respective mice on HFD.
CD40L deficiency does not improve high fat diet-induced
insulin resistance
Insulin resistance and elevated fasting blood glucose levels have
been reported to be associated with elevated CD40L plasma levels
in humans [28]. As expected, plasma glucose levels were
significantly higher in HFD-consuming animals after 8 and 20
weeks of diet compared with animals consuming LFD in our study
(data not shown). While glucose levels did not differ between
CD40L
2/2 and wild-type mice at week 20 (Figure 3 B), plasma
insulin levels decreased by 6468% (p=0.03, n$5 per group) in
CD40L
2/2 mice consuming HFD (Figure 3 C). These data
suggested an increased insulin sensitivity of CD40L-deficient mice.
However, CD40L
2/2 mice did not show improved insulin
tolerance after 8 and 20 weeks on HFD compared with
corresponding control animals (Figure 3 C, D). Also, CD40L-
deficiency did not alter intraperitoneal glucose tolerance testing at
both time points of the study (Figure 3 E, F).
To gain more insight into the role of CD40L on insulin
sensitivity we performed hyperinsulinemic-euglycemic clamps in
HFD-consuming animals. Interestingly, glucose infusion rate
(GIR) tended to decrease in CD40L
2/2 mice compared with
WT controls, whereas insulin-mediated glucose disappearance
(Ins-GDR) was not altered (Figure 2 A, B). Basal glucose
disappearance/appearance (basal GDR) tended to increase in
CD40L-deficient mice (Figure S2 C). Glucose uptake into
peripheral muscle tissue and heart muscle decreased or tended
to decrease in CD40L-deficient mice, while glucose uptake into
adipose tissue was only modulated in subcutaneous, but not in
visceral or brown adipose tissue in CD40L-deficient mice (Figure
S2 E), suggesting tissue-specific peripheral insulin resistance in
these mice. Moreover, gene expression of insulin-receptor 1 (IRS-
1), glucose-transporter 4 (GLUT-4), and gluconeogensis regulating
phosphoenolpyruvate carboxykinase (PEPCK) was potently regu-
lated in different tissues in CD40L
2/2 mice (Figure S2 F–K),
further supporting involvement of CD40L in glucose homeostasis.
CD40L deficiency aggravates diet-induced hepatic
steatosis
Dyslipidemia and non-alcoholic hepatic steatosis (NASH) are
well established features of the metabolic syndrome [33].
Villeneuve et al. recently reported that CD40L might serve as
protective factor in hepatic steatosis – demonstrating progressive
hepatic inflammation and hampered secretion of lipoproteins in
the blood of CD40L
2/2 mice [34]. Accordingly, we observed that
low-density lipoproteins (LDL) were reduced by 6368% (p=0.01,
n=8 per group) in CD40L-deficient mice after 20 weeks of diet,
while total plasma cholesterol, triglycerides, and free fatty acids did
CD40L and the Metabolic Syndrome
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2/2 mice and respective controls
(Table 1). Interestingly, relative liver weights were reduced in
CD40L
2/2 mice by 1566% (p=0.01, n=22) in the HFD group
(Figure 4 A). Hepatic steatosis is characterized by excessive fat
accumulation within the liver [35]. Correspondingly, liver lysates
from CD40L-deficient mice contained significantly higher
amounts of triglycerides regardless of the diet consumed (Figure 4
B). In accord, cholesterol accumulation in the HFD-group
increased by 163660% in CD40L
2/2 mice (p=0.03, n=6,
Figure 4 C). Moreover, macroscopic and histological analysis
showed enhanced accumulation of fat-specific Oil-red-O-positive
staining, augmented lipid droplets, and increased vacuole
formation in livers of CD40L2/2 mice (Figure 4 D). Accordingly,
master regulators involved in lipid metabolism, such as the
transcription factors peroxisome proliferator-activated receptor
alpha (PPARa), carbohydrate responsive element-binding protein
(ChREBP), and sterol regulatory element-binding protein-1
(SREBP1c), as well as factors required for lipid synthesis such as
free fatty acid synthase (FAS) and acetyl-CoA-carboxylase 1
(ACC1) were potently regulated in CD40L
2/2 liver tissue (Figure 4
E–I). However, we did not observe decrease of apolipoprotein-
B100 (ApoB100) as previously described [34] (Figure 4 J).
CD40L deficiency attenuates diet-induced adipose tissue
inflammation and down-regulates local and systemic
chemokine gene expression
Adipose tissue macrophages (ATMs) accumulate in DIO as
previously reported and are considered a marker of adipose tissue
inflammation [12]. The latter is considered instrumental for the
pathogenesis of the metabolic syndrome and its subsequent clinical
complications. As expected, macrophage infiltration was elevated
in visceral fat pads of wild-type mice consuming HFD for 20 weeks
by 166662% (p=0.03, n$7 per group, data not shown)
compared with those from wild-type mice on LFD diet as assessed
by immunhistochemical analysis of F4/80-positive cells in adipose
tissue sections and real-time PCR analysis. This increase in
inflammatory cell infiltration was absent in mice lacking CD40L
(Figure 5 A–C). Interestingly, CD40L-deficiency did only affect
total numbers of infiltrating macrophages, but not macrophage
diversity, since numbers of CD11c
+ M1-macrophages were not
changed in CD40L
2/2 mice (Figure 5 D). Also, mRNA
abundance of M2-Marker Arginase-1 was not changed in adipose
tissue (data not shown). B-cells infiltrate adipose tissue upon DIO
as shown recently [15] and were reduced in CD40L
2/2 mice in
Figure 1. Genetic deficiency of CD40L does not protect from diet-induced obesity. WT and CD40L
2/2 mice consumed a high fat diet (HFD)
for 20 weeks. Relative increase of body weight (shown as % of body weight at week 0) and total body fat as assessed by MRI-based body composition
analysis are shown for the indicated time points (A, B). Weight of epididymidal (EFP), peri-renal (RFP), and cardiac fat pads (CFP) fat are displayed as
percentage of total body weight (BW, C). Data are presented as mean 6 SEM of at least 15 mice per group.
doi:10.1371/journal.pone.0033026.g001
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content rose upon consumption of HFD [9], but was not affected
by CD40L-deficiency in both groups (Figure 5 F). Likewise,
number of CD4+ T-helper cells showed no differences between
the groups (Figure 5 G). Regulatory T-cells – physiologically
resident in lean adipose tissue [11] – increased in adipose tissue of
CD40L
2/2 mice consuming HFD compared with wild-type mice
consuming HFD (Figure 5 H), suggestive of a protective phenotype
in these mice. Adipocyte size correlates with obesity and the
metabolic syndrome [36]. In CD40L-deficient mice mean
adipocyte diameter was reduced compared with corresponding
wildtype mice after HFD-feeding (Figure 5 I). Also, relative
cholesterol content tended to decrease in adipocyte lysates of
CD40L
2/2 mice (Table 1).
To explore potential mechanisms of these findings we evaluated
chemokine expression in adipose tissue. We previously reported
that CD40L induces secretion of pro-inflammatory cytokines and
chemokines including MCP-1 in various cell types including
adipose cells [27,37]. Whereas gene expression of both chemokines
RANTES and MCP-1 were induced by HFD (data not shown),
only MCP-1 proved to be regulated by CD40L showing a
significant reduction in adipose tissue of CD40L
2/2 mice
consuming HFD compared with respective controls (Figure 6 A).
Accordingly, CD40L-deficient mice consuming HFD for 20 weeks
had significantly lower plasma levels of MCP-1 (Figure 6B), while
levels of other inflammatory cytokines, such as IL-12, IL-10, IFN-
c, IL-6 or TNF-a were not modulated by CD40L-deficiency after
HFD-consumption (Figure S3 A–E), indicating that CD40L
specifically regulates gene expression of MCP-1.
Deficiency of CD40L modifies balance of B-cell subsets
and reduces levels of circulating auto-antibodies against
oxidized lipids
CD40L-dependent co-stimulatory pathways regulate funda-
mental B-cell functions, such as activation, proliferation, and
induction of IgG-antibody class switch [20]. Since B-cell
accumulation in adipose tissue was reduced in mice lacking
CD40L, we explored whether CD40L deficiency alters balance of
different B-cell subsets. While total numbers of peripheral CD19
+
B-cells were not affected by the absence of CD40L (Figure 7A), B-
cells resident in the peritoneal cavity decreased in CD40L
2/2
mice. This decrease was observed in both, innate-like B-cell
subsets, such as B1a and B1b cells (Figure 7B, C), and in
conventional B2-cells which mainly act in acquired immunity
(Figure 7D). Surprisingly, regulatory CD1d
+CD5
+CD19
+ B-cells –
regarded as distinct subset suppressing T-cell mediated inflamma-
tion and thereby exhibiting anti-inflammatory actions [38] –
increased by 88627% in CD40L
2/2 mice (p=0.01, n$18 per
Figure 2. CD40L deficiency does not affect basic energy metabolism. WT and CD40L
2/2 mice consumed a high fat diet (HFD) for 20 weeks.
Plasma levels of leptin (A) and adiponectin (B) were determined at the indicated time points by ELISA. Food intake (C), heat production (D),
ambulatory movement (E), and respiratory exchange ratio (RER, F) were analyzed in metabolic cages. CaH and fat indicate carbohydrate and fat
metabolism (F). Data are presented as mean 6 SEM of at least 9 mice per group.
doi:10.1371/journal.pone.0033026.g002
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suppressive B-cell subsets in CD40L-deficient mice. The increase
in protective B-regulatory cells was also observed in spleens of
CD40L
2/2 mice (data not shown). DIO was recently reported to
induce production of pathogenic, auto-reactive IgG antibodies by
B2-cells [15]. Since LDL plasma levels strongly increased in DIO
mice (Figure 4B) and diabetes is associated with increased
oxidative stress, we tested the occurrence of OxLDL-specific
antibodies in our mice. IgG-antibodies against malondialdehyde-
modified LDL (MDA-LDL) and copper-oxidized LDL (CuOx-
LDL) were strongly up-regulated in HFD-consuming wildtype
mice compared with LFD. Interestingly, this increase in anti-
OxLDL antibodies was absent in CD40L-deficient mice
(Figure 7F), suggesting that the effects observed might be caused
by reduced levels of pro-inflammatory IgG antibodies.
Discussion
Chronic inflammation plays a key role in obesity, and hallmarks
of adipose tissue inflammation, such as infiltration of immune cells
Figure 3. Absence of CD40L does not ameliorate insulin sensitivity in diet-induced obesity. Plasma glucose (A) and insulin levels (B) were
determined in animals fasted overnight (A) and for 6 hours (B) overnight. Insulin tolerance (ITT) and glucose tolerance testing (GTT) were performed
after intraperitoneal insulin (0.5 U/kg lean body mass) or glucose (1 g/kg lean body mass) injection (C–F). Inlays represent area under the curve
calculation (AUC) of the indicated glucose curve.
doi:10.1371/journal.pone.0033026.g003
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pathogenesis of various other inflammatory pathologies, such as
atherogenesis [4]. Despite the extensive characterization of cellular
fractions resident in adipose tissue and their contribution to
adipose tissue inflammation, the exact pro-inflammatory pathways
underlying these phenomena remain incompletely understood.
CD40L potently regulates B- and T-cell function and figures
prominently in the initiation and progression of a variety of
chronic inflammatory diseases, including atherosclerosis [20,22].
Here, we report that genetic deficiency of CD40L attenuates
adipose tissue inflammation in a mouse model of diet-induced
obesity. Most likely, this effect was caused (1) by down-regulation
of the pro-inflammatory chemokine MCP-1 resulting in reduced
immune cell recruitment to inflamed adipose tissue and (2) by
Figure 4. Genetic deficiency of CD40L aggravates diet-induced hepatic steatosis. Liver weight is shown after 20 weeks of HFD (A). Hepatic
triglycerides and cholesterol was measured in liver lysates (B,C). Liver sections were stained with lipid-specific oil-red-O (ORO, E). RNA abundance of
peroxisome proliferator-activated receptor alpha (PPARa), carbohydrate responsive element-binding protein (ChREBP), sterol regulatory element-
binding protein-1 (SREBP1c), free fatty acid synthase (FAS), acetyl-CoA-carboxylase 1 (ACC1), apolipoprotein-B100 (ApoB100) was determined by real-
time PCR in whole liver tissue after 20 weeks of HFD (E–J). Data are presented as mean 6 SEM of at least 6 animals per group.
doi:10.1371/journal.pone.0033026.g004
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IgG antibodies. MCP-1, a potent chemotactic factor for
monocytes implicated in a variety of inflammatory diseases
including atherosclerosis [39], has previously been shown to
regulate inflammatory cell infiltration to adipose tissue in diet-
induced obesity [40]. In vitro, our group and others recently
demonstrated initiation of MCP-1 gene- and protein expression by
CD40L in several cell types including adipose cells [27,31,37].
Interstingly, expression of other inflammatory chemokines such as
RANTES and CXCL-1 remained unaffected by CD40L deficien-
cy pointing towards a specific role of MCP-1 in adipose tissue
inflammation. Notably, regulation of MCP-1 gene expression
might not be restricted to adipocytes, but could also be secondary
to diminished inflammatory cell recruitment in these mice.
Adipose tissue inflammation is orchestrated by infiltration,
accumulation, and interaction of a plethora of immune cells,
such as B- and T-cells, macrophages, and mast cells. Interest-
ingly, B-cell infiltration occurs early in disease progression and
seems to promote further disease progression [15,41]. In our
study, B-cell accumulation in adipose tissue was strongly reduced
in CD40L
2/2 mice, while B-cell diversity shifted towards anti-
inflammatory subsets, such as B-regulatory cells. This is
supported by numerous reports showing that CD40L-associated
pathways fundamentally regulate B-cell physiology and patho-
physiology in various disease models [20,42]. We also propose
that the production of pathogenic antibodies by B-cells, as
exemplarily shown for OxLDL, contributes to the effects
observed as previously suggested by others [15]. As demonstrat-
ed previously, oxidation-specific epitopes, such as oxidized LDL
represent major targets of protective natural IgM antibodies
[43], but are also recognized by potentially pathogenic T-cell
dependent IgG antibodies as a result of pathological T-cell
activation, which is impaired in CD40L deficient mice. We
cannot exclude that regulation of immune cells apart from B-
cells by B-regulatory cells might result in a protective phenotype.
Also, infiltration of T-cell subsets, such as CD4
+,C D 8
+,a n dT -
regulatory cells, was identified as crucial event in the initiation of
adipose tissue inflammation [9,11,44]. However, the content of
CD8+ and CD4
+ cells was not altered by CD40L deficiency in
our study. Numbers of regulatory T-cells decreased during DIO
and persisted on a higher level in CD40L
2/2 mice. Of note, a
decrease of T regulatory cells has been proposed to mediate the
onset of the metabolic syndrome while accumulation of CD8+ T-
cells has been suggested to promote disease progression [11].
This is well in accord with our findings that diet-induced fat
depositions as assessed by MRI body composition analysis were
only blunted in the early stages of diet-induced obesity by
CD40L-deficiency. Also, the slight increase in relative weight
gain occurred in the late stages of DIO in CD40L
2/2 mice,
while total body weight did not differ between both genotypes. In
accord with this, it has been shown that both, B-cell deficiency
and B-cell depletion reduce inflammatory cell accumulation in
adipose tissue while not affecting the development of obesity
[15]. In fact, CD40L might be more important for the initiation
of obesity, rather than its propagation.
Importantly, food intake, heat production, and respiratory
exchange ratio were not altered in CD40L
2/2 mice, ruling out an
effect of CD40L on basic energy metabolism affecting our results.
However, we cannot exclude that CD40L directly affects the
regulation of growth hormones since levels of somatostatin, GnRH
or IGF-1 were modulated in CD40L
2/2 mice on LFD, potently
affecting weight and metabolic characteristics in these mice.
However, growth hormone levels were not altered in mice
consuming HFD.
Table 1. Baseline study characteristics.
LFD HFD
WT CD40L
2/2 p-value WT CD40L
2/2 p-value
Total body weight at week 0 (g) 25.360.4 22.860.4 ,0.01
Total body weight at week 20 (g) 41.960.7 31.2060.8 ,0.01 42.960.6 41.760.7 0.18
Lean body mass at week 0 (% body weight) 95.060.66 94.160.65 0.38 93.960.62 93.060.50 0.24
Lean body mass at week 20 (% body weight) 76.160.7 81.261.6 ,0.01 64.660.7 64.160.93 0.69
Heart weight (% BW) 0.4160.02 0.4460.01 0.26 0.3760.02 0.3960.02 0.41
Spleen weight (% BW) 0.2960.02 0.2160.01 ,0.01 0.3460.02 0.2960.02 0.12
Kidney weight (% BW) 1.160.04 1.160.03 0.12 1.060.04 0.960.04 0.69
Blood pressure at week 0 (mmHg) 92.461.3 100.161.3 ,0.01
Blood pressure at week 20 (mmHg) 94.762.7 94.962.2 0.94 97.461.7 100.762.1 0.21
Serum total cholesterol at week 20 (mmol/l) 1.860.1 2.060.4 0.17 2.760.4 2.460.4 0.56
Serum LDL-cholesterol at week 20 (mmol/l) 0.1260.03 0.0560.01 0.03 0.3660.06 0.2260.06 0.1
Serum Triglycerides at week 20 (mmol/l) 0.9160.09 0.7460.03 0.1 0.7760.07 0.7460.03 0.36
Serum free fatty acids (ng/ml) ND ND 449.5629.9 470.5621.1 0.57
Adipocyte Cholesterol content/PC ND ND 1.2560.2 1,1460.3 0.79
CD8
+ T-cells (% CD3+)3 4 . 9 60.7 30.260.8 ,0.01 27.861.3 29.660.6 0.17
CD4
+ T-cells (% CD3+)5 5 . 8 61.1 60.161.2 0.02 56.561.2 59.960.5 0.01
CD115
+GR-1
+ monocytes (%) 18.863.6 7.561.6 0.02 18.862.7 14.962.3 0.28
Splenic T-cells (% splenocytes) 28.061.0 26.860.6 0.37 25.660.8 20.960.7 ,0.01
Splenic T-regulatory cells (%) 12.160.5 5.960.6 ,0.01 13.260.4 6.860.3 ,0.01
Data are presented as mean 6 SEM, ND not determined, LFD low fat diet, HFD high fat diet, WT wildtype, PC Phosphatidylcholine, BW body weight.
doi:10.1371/journal.pone.0033026.t001
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metabolic syndrome. Poggi et al. demonstrated that stimulation
with recombinant CD40L impaired insulin-induced glucose
uptake in adipocytes by down-regulating expression of insulin
receptor-1 (IRS-1) and glucose transporter-4 (GLUT-4), proposing
CD40L as direct regulator of insulin and glucose tolerance [31]. In
accord with these findings, we observed increased IRS-1 and
GLUT-4 mRNA expression in liver and skeletal muscle. Also,
insulin levels were strongly down regulated in CD40L-deficient
mice under both dietary regimens, suggesting a role of CD40L in
insulin resistance. However, we could not confirm functional
relevance of these observations in CD40L
2/2 mice, since fasting
glucose levels and GTT/ITT did not differ between CD40L
2/2
and corresponding WT mice consuming HFD for 20 weeks. On
the other hand, CD40L-deficient mice consuming LFD demon-
strated improved GTT and ITT (data not shown), but these effects
might be secondary to diminished weight gain and smaller fat
depots in these mice [45]. Conversely, in clamps analysis, GIR
tended to decrease in CD40L
2/2 mice on HFD, which might be
caused by diminished glucose uptake in skeletal muscle – but not
in visceral adipose tissue – as observed in our study. These findings
indicate a trend towards an aggravation of muscle insulin
sensitivity in CD40L
2/2 mice – albeit without systemic relevance.
Overall, more mechanistic workup, including description of insulin
secretion and insulin receptor signaling in CD40L-deficient mice
will be needed to define the exact role of CD40L in insulin and
glucose homeostasis.
Obesity correlates with hepatic steatosis [46]. Surprisingly, we
found that mice lacking CD40L exhibited a strong increase in
hepatic accumulation of triglycerides and cholesterol. Histological
analysis showed augmented vacuole formation and an increased
number of lipid droplets, consistent with aggravated hepatic
steatosis. In line with our findings, Villeneuve et al. recently
proposed CD40L as protective factor of hepatic steatosis
demonstrating increased hepatic steatosis in CD40L-deficient
mice consuming a diet rich in olive oil [34]. The authors showed
that this effect was most likely caused by an inhibition of apoB100
and very low density lipoprotein (VLDL) secretion in CD40L
2/2
mice and subsequently lipid accumulation in the liver. Accord-
ingly, we found that concentration of apoB100 containing low
density lipoproteins (LDL) was markedly reduced in CD40L-
deficient mice in our study, while – as previously described – total
plasma cholesterol and triglycerides were not affected [47]. Since
this effect was present in both diet arms of our study, we assume
that CD40L might indeed be a regulator of hepatic steatosis
independently of dietary free fatty acid intake. This was further
supported by the fact that CD40L deficiency modulated liver-
specific gene expression of transcription factors and enzymes
linked to lipid metabolism, including PPARa, SREBP1c, or FAS.
Of note, we did not observe down-regulation of apoB100 as
described previously. Therefore, the exact pathways involved have
to be further evaluated.
Hypertension is considered an integral part and trigger of the
metabolic syndrome. Of note, systolic blood pressure in CD40L
2/2
mice was significantly higher than in corresponding WT mice at the
begin of the feeding study. This increase in blood pressure was most
likely not caused by a pro-inflammatory vascular phenotype. This
was further supported by the fact that both, systolic blood pressure
and levels of pro-inflammatory cytokines showed no difference in
both dietary arms at the end of the study.
Since reduction of inflammatory cell accumulation in adipose
tissue occurred in CD40L-deficient mice without affecting the
metabolic phenotype, our findings furthermore propose the
existence of specific inflammatory pathways in DIO. In line with
this, the inflammatory stimulus of HFD might overwhelm the anti-
inflammatory capacity in CD40L-deficient animals. This might
also be reflected by the fact that inflammatory cytokine levels were
blunted in CD40L
2/2 mice on LFD, but not on HFD.
In summary, we present the novel finding that deficiency of
CD40L specifically attenuates diet-induced adipose tissue inflam-
mation in mice while not affecting DIO itself and its associated
metabolic complications, such as insulin resistance. Our data
contribute to the understanding of inflammatory pathways in the
metabolic syndrome and may have implications on the develop-
ment of novel anti-inflammatory therapeutic strategies to fight MS
and other chronic inflammatory conditions.
Materials and Methods
Ethics statement
All experimental protocols were approved by the animal ethics
committee (AEC) of the Alfred Medical Research and Education
Figure 6. Genetic absence of CD40L reduces MCP-1 gene
expression in adipose tissue and MCP-1 plasma levels. Diet-
induced obesity was induced by feeding with a high fat diet for 20
weeks. MCP-1 gene transcripts in adipose tissue were quantified by
quantitative PCR after whole tissue RNA preparation and normalization
for GAPDH expression (A). Levels of circulating MCP-1 were determined
in plasma by cytometric bead array. Data are presented as mean 6 SEM
of at least 6 animals per group.
doi:10.1371/journal.pone.0033026.g006
Figure 5. CD40L deficiency attenuates diet-induced adipose tissue inflammation by reduction of immune cell infiltration. Wildtype
(WT) and CD40L2/2 mice consumed HFD for 20 weeks. Infiltration of macrophages was quantified by detection of the F4/80 antigen in
immunohistochemistry (A, B) and quantitative PCR (C). CD11c-expressing M1-macrophages were determined by flow cytometry (D). B-cells were
defined as CD19-positive cells in flow cytometry after enzymatic digestion of adipose tissue and specific anti-CD19 staining (C). Numbers of CD8
+
cytotoxic and CD4
+ T-helper-cells were quantified by detection of specific mRNA transcripts in whole tissue RNA preparations and normalized to
GAPDH (F, G). Regulatory T-cells were defined as CD4
+CD25
+FoxP3
+ cells in flow cytometry (H). Mean adipocyte diameter was calculated in
histological sections by image-processing software (I). Data are presented as mean 6 SEM of at least 6 animals per group.
doi:10.1371/journal.pone.0033026.g005
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approved project number E/0779/2008/B.
Animals
CD40L
2/2 mice on a C57BL/6J background and aged-
matched wildtype mice (WT) were obtained from Jackson
Laboratory (USA). To induce the metabolic syndrome 8-week
old, male animals received a high-fat diet (HFD) containing 23%
fat, 18.4% protein, 16.8 MJ/kg digestible energy (Research Diet
D12451, Specialty Feeds, Australia) for 20 weeks. Control animals
consumed LFD containing 4.6% fat, 19.6% protein, 14.3 MJ/kg
digestible energy (Specialty Feeds, Australia). All mice were
maintained under a 12-hour light, 12-hour dark cycle and had
access to food and water ad libitum unless indicated otherwise. At
the end of the study overnight-fasted animals were euthanized,
blood and organs were collected and analyzed as described below.
Body composition analysis
Composition of total fat, lean and water mass was assessed by
MRI-based body composition analysis (EchoMRI, Echo Medical
Systems, USA) on a basis of 4-weekly follow-up measurements.
Intraperitoneal glucose and insulin tolerance testing
Glucose and insulin tolerance testing was performed after 8 and
20 weeks after start of the diet. For glucose tolerance tests (GTT)
mice were deprived of food 6 hours prior to the procedures and
received intraperitoneal glucose injections (1 g/kg lean body mass
as assessed by body composition analysis). For insulin tolerance
tests (ITT) mice were injected with human insulin intraperitoneally
(0.5 U/kg, Actrapid Insulin, Novo Nordisk, Denmark). Blood
samples were collected at 0, 15, 30, 45, 60, 90 and 120 minutes
after the insulin challenge. Plasma glucose concentration was
measured with AccuChek GO (Roche Diagnostics, Switzerland).
Insulin measurements
Plasma insulin levels were determined at the end of the feeding
study by a commercial ELISA kit (Millipore). Animals were
deprived of food 6 hours prior to blood sampling.
Euglycemic-hyperinsulinemic clamp (EHC)
After 20 weeks on diet animals were subjected to euglycemic-
hyperinsulinemic clamps. Four days prior to the euglycemic-
hyperinsulinemic clamp mice were anaesthetized and an indwell-
ing catheter was placed into the right internal jugular vein. Mice
were allowed to recover for 4 days following surgery and body
weight was monitored daily. On the day of the clamp mice were
fasted for 5 hours followed by a continuous infusion of [3-
3] Hg-
labeled glucose (5 mCi bolus and 0.05 mCi/min) to measure basal
glucose turnover. After infusion of the tracer for 2 hours EHC was
performed. A continuous infusion of insulin (4 mU/kg/min) was
started. Blood (5 mL) was sampled from the tail vein every 10 min
to measure glucose levels and euglycemia was maintained using a
variable infusion of 30% glucose. To determine glucose specific
activity, small blood samples were taken regularly during the
clamp. To measure the tissue glucose uptake, a bolus of 2[
14C]
deoxyglucose (12 m Ci) was injected. Blood concentrations of
[3-
3H] glucose and 2[
14C] deoxyglucose were determined after
deproteinization using BaOH and ZnSO4. Glucose uptake into
Figure 7. Deficiency of CD40L modifies balance of B-cell subsets and reduces levels of circulating auto-antibodies against oxidized
lipids. Numbers of peripheral CD19-positive B-cells (A), peritoneal CD19
+CD5
+CD11b
+ B1a-cells (B), peritoneal CD19
+CD5
2CD11b
+ B1b-cells (C), and
peritoneal CD19
+CD5
2CD11b
2 B2-cells (D) were determined by flow cytometry. Regulatory B-cells were defined as CD19
+CD5
+CD1d
+ cells in the
peritoneal cavity (E). Levels of circulating antibodies against the indicated epitopes were determined by chemiluminescent ELISA (F). Data are
presented as mean 6 SEM of at least 15 animals per group.
doi:10.1371/journal.pone.0033026.g007
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2[
14C] deoxyglucose-6-phosphate and the plasma 2 [
14C]
deoxyglucose profile.
Metabolic caging
Animals were allowed to acclimatize to metabolic cages
(Oxymax/CLAMS, Columbus Instruments, USA) for a period
of 24 hours before start of analysis. During the 24 hour
observation period food intake, ambulatory movement, heat
production, O2 consumption and CO2 production were assessed
and recorded.
Preparation of the stromal vascular fraction
Murine epididymal fat pads were minced and digested with
collagenase for 30 minutes at 37uC (0.5 mg/ml, Collagenase B,
Roche, Switzerland). Digested tissue was filtered through a nylon mesh
(100 mm). The stromal vascular fraction (SVF) and adipocyte fraction
were obtained from the resulting pellet and supernatant, respectively.
Preparation of splenocytes
Cells were released from spleen by nicking the capsule and
gently rotating two microscope slides. Cell suspension was filtered
through a nylon mesh (100 mm) and pelleted.
Flow cytometry
The stromal vascular fraction (SVF) and splenocytes were
obtained as described above. Remaining red blood cells were
removed by FACS Lysing solution (BD Biosciences, USA). Cells
were washed in PBS and Fc-Receptors were blocked by anti-
CD16/CD32 (eBioscience, USA) for 10 minutes on ice. Cells were
then labeled with the indicated antibodies before quantification
with a flow cytometer (BD FACS Canto II, BD, USA). Following
antibodies were used: anit-CD8-PE, anti-CD4-FITC, anti-CD3-
APC, anti-CD25-PE, anti-Foxp3-APC, anti-CD19-APC, anti-
CD115-PE, anti-Ly6G/C-FITC, anti-F4/80-PE and anti-
CD11c-APC (all from eBioscience, USA).
Isolation of total RNA and quantitative real-time PCR
Organs were stored in RNAlater (Qiagen, USA) after harvest.
RNA was extracted from epididymal adipose tissue using TRIzol
Reagent (Invitrogen, USA) and glycogen as a coprecipitator
(Roche, Switzerland). Homogenization was performed using a
rotor-stator dispergator (IKA, Germany). 1 mg of total RNA was
transcribed into cDNA using the Transcriptor First Strand cDNA
Synthesis Kit (Roche, Switzerland). Subsequent quantitative real-
time PCR was performed with a LightCycler 480 System with the
LightCycler 480 SYBR Green I Master (Roche, Switzerland)
detection format. Murine GAPDH served as control. Primer
sequences are avaible upon request.
Histology, immunhistochemistry (IHC)
Adipose tissue was fixed for 24–48 hours with 10% parafor-
maldehyde solution (Sigma-Aldrich, USA) at 4uC, dehydrated,
embedded in paraffin, and cut into 6 mm sections. Sections were
mounted on glass slides and depleted of paraffin and rehydrated.
Sections were then placed in pre-heated Target Retrieval Solution
(Dako, USA) and rinsed with PBS. For IHC staining sections were
blocked with 4% rabbit serum, incubated for 1.5 hours at RT with
anti-F4/80 (Abcam, USA) and detected by an appropriate
secondary antibody followed by detection with AEC+ substrate
(DAKO, USA). Liver sections were fixed in 10% neutral buffered
formalin (Harleco, USA) for 10 minutes, rinsed with water,
submerged in 100% Polypropylene glycol (Fischer Chemicals,
Switzerland) for 2 minutes, incubated in Oil-Red-O staining
solution (Sigma-Aldrich, USA) for 25 minutes at 60uC, washed in
Millipore water and 0.05% Ammonia H2O.
Analysis of murine plasma samples
Plasma levels of insulin, leptin, adiponectin, FFAs and the
indicated growth hormones were measured by ELISA according
to the manufacturers’ protocols (Mercodia, Sweden; R&D
Systems, USA; Cusabio, USA; Uscn Life Science Inc, China).
Triglyceride, LDL, HDL, and total cholesterol levels of murine
plasma samples were assessed by COBAS Integra 400 plus system
(Roche Diagnostics, Switzerland). Plasma cytokines were deter-
mined by a cytometric bead array (CBA, BD Biosciences, USA)
according to the manufacturers’ protocol.
Liver Homogenisates
Liver samples were homogenized in 200 ml PBS using a
dispergator (IKA, Germany) and normalized to a protein
concentration of 2.5 mg/ml. Lipids were extracted according to
Folch et al. [48]. Samples were analyzed by liquid chromatogra-
phy-mass spectrometry on a 4000QTRAP
TM LC/MS/MS system
(Applied Biosystems, USA).
Measurement of antibody titers
Plasma titers of antibodies to the indicated antigens were
determined by chemiluminescent ELISA as previously described
[49].
Statistical analysis
Data are presented as means 6 SEM and were analyzed by 2-
tailed Student’s t-test. P-values,0.05 were considered significant.
Supporting Information
Figure S1 WT and CD40L
2/2 mice consumed a stan-
dard low fat diet (LFD) for 20 weeks. Relative increase of
body weight (shown as % of body weight at week o) and total body
fat as assessed by MRI-based body composition analysis are shown
for the indicated time points (A, B). Weight of epididymidal (EFP),
peri-renal (RFP), and cardiac fat pads (CFP) fat are displayed as
percentage of total body weight (BW, C). Plasma levels of leptin
were determined at the indicated time points (D). Food intake (E),
heat production (F), ambulatory movement (G), and respiratory
exchange ratio (RER, H) were analyzed in metabolic cages.
Growth hormone levels were determined by ELISA (I–K). Data
are presented as mean 6 SEM of at least 15 mice per group (A–D,
H–J) or 9 mice per group (E–H).
(TIF)
Figure S2 Hyperinsulinemic-euglycemic clamp analysis
after 20 weeks of HFD revealed rate of glucose infusion
rate (GIR, A), glucose disappearance under clamp (Ins-
GDR, B) and basal conditions (GDR, C). Glucose uptake in
peripheral muscle and heart tissue (D) and fat tissue (E) was
determined by specific glucose tracer uptake. RNA abundance of
insulin-receptor 1 (IRS-1), glucose transporter 4 (GLUT-4) and
phosphoenolpyruvate carboxykinase (PEPCK) was quantified by
real time PCR and normalization to GAPDH (F–K). Data are
presented as mean 6 SEM of at least 9 mice per group.
(TIF)
Figure S3 Plasma levels of inflammatory cytokines
were determined by cytometric bead array after 20
weeks of standard diet (LFD) or high fat diet (HFD).
(TIF)
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